Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Gains from Sales and Divestitures (2017 - 2025)

Historic Gains from Sales and Divestitures for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $608833.0.

  • Aclaris Therapeutics' Gains from Sales and Divestitures rose 1215.57% to $608833.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $608833.0, marking a year-over-year increase of 1215.57%. This contributed to the annual value of $1.5 million for FY2024, which is 9768.8% up from last year.
  • Aclaris Therapeutics' Gains from Sales and Divestitures amounted to $608833.0 in Q3 2025, which was up 1215.57% from $595035.0 recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Gains from Sales and Divestitures registered a high of $1.5 million during Q4 2024, and its lowest value of $377371.0 during Q1 2021.
  • For the 5-year period, Aclaris Therapeutics' Gains from Sales and Divestitures averaged around $720474.9, with its median value being $542846.0 (2024).
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first plummeted by 6089.24% in 2022, then surged by 9768.8% in 2024.
  • Over the past 5 years, Aclaris Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $1.3 million in 2021, then plummeted by 60.21% to $533212.0 in 2022, then surged by 39.77% to $745279.0 in 2023, then skyrocketed by 97.69% to $1.5 million in 2024, then crashed by 58.68% to $608833.0 in 2025.
  • Its last three reported values are $608833.0 in Q3 2025, $595035.0 for Q2 2025, and $525753.0 during Q1 2025.